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BACKGROUND. Prostate cancer (PCa) affects more than 190,000 men each year with 10%
of men diagnosed at 55 years, that is, early onset (EO) PCa. Based on historical findings for
other cancers, EO PCa likely reflects a stronger underlying genetic etiology.
METHODS. We evaluated the association between EO PCa and previously identified single
nucleotide polymorphisms (SNPs) in 754 Caucasian cases from the Michigan Prostate Cancer
Genetics Project (mean 49.8 years at diagnosis), 2,713 Caucasian controls from Illumina’s
iControlDB database and 1,163 PCa cases diagnosed at >55 years from the Cancer Genetic
Markers of Susceptibility Study (CGEMS).
RESULTS. Significant associations existed for 13 of 14 SNPs (rs9364554 on 6q25, rs10486567
on 7p15, rs6465657 on 7q21, rs6983267 on 8q24, rs1447295 on 8q24, rs1571801 on 9q33,
rs10993994 on 10q11, rs4962416 on 10q26, rs7931342 on 11q13, rs4430796 on 17q12, rs1859962
on 17q24.3, rs2735839 on 19q13, and rs5945619 on Xp11.22, but not rs2660753 on 3p12). EO
PCa cases had a significantly greater cumulative number of risk alleles (mean 12.4) than
iControlDB controls (mean 11.2; P ¼ 2.1  1033) or CGEMS cases (mean 11.9;
P ¼ 1.7  105). Notably, EO PCa cases had a higher frequency of the risk allele than CGEMS
cases at 11 of 13 associated SNPs, with significant differences for five SNPs. EO PCa cases
diagnosed at <50 (mean 12.8) also had significantly more risk alleles than those diagnosed at
50–55 years (mean 12.1; P ¼ 0.0003).
CONCLUSIONS. These results demonstrate the potential for identifying PCa-
associated genetic variants by focusing on the subgroup of men diagnosed with EO disease.
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INTRODUCTION
In 2009, prostate cancer (PCa) was the most com-
monly diagnosed non-cutaneous cancer among men
in the United States with an estimated 192,280 new
cases and the second leading cause of cancer-related
mortality with an estimated 27,360 PCa-related deaths
[1]. Although PCa is commonly considered to be a
disease of older men, with 63% of men diagnosed
over the age of 65, last year over 9% of men diagnosed
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were 55 years. The proportion of men diagnosed at
younger ages has increased steadily since the intro-
duction of widespread screening with prostate-
specific antigen (PSA) and continues to rise despite an
apparent stabilization in PCa incidence overall [2,3].
This is despite guidelines for PCa early detection that
have previously targeted men starting at age 50
except for those perceived to be at increased risk of
disease, that is, those with African American ancestry
and/or a family history of PCa, who may begin
screening 5–10 years earlier [4,5]. PCa in younger
men may have different public health implications,
since some data suggest that compared to older men
with similar clinical features younger men may be
more likely to die of their cancer [6], especially those
diagnosed with higher grade or locally advanced
disease [7].
Early age at diagnosis is a recognized marker of
genetic susceptibility for several hereditary cancers
including breast [8], colorectal [9], ovarian [10], and
endometrial [11] cancer. Among hereditary PCa fami-
lies, risk increases with decreasing age of diagnosis of
affected relatives [12] and, on average, hereditary PCa
is diagnosed 6–7 years earlier than sporadic PCa [6].
Because the lower incidence of PCa at younger ages
may indicate the lower overall prevalence of other
risk factors for the disease [13], early onset (EO) PCa
cases, that is, PCa cases diagnosed 55 years of age,
may provide an especially rich sub-group of men
among whom to search for genes associated with PCa
risk.
Several recent genome-wide association studies
(GWAS) have provided statistically significant evi-
dence for multiple independent loci associated with
PCa [14–21]. Efforts to distinguish those loci that may
be associated with aggressive PCa, a clinically import-
ant form of PCa that is most likely to impact survival,
have also been pursued [22–25]. In this study, we
evaluate the evidence for association between risk of
EO PCa and 14 single nucleotide polymorphisms
(SNPs) distributed across 10 chromosomes in a
sample of 754 unrelated Caucasian American EO PCa
cases from the University of Michigan Prostate Can-
cer Genetics Project (UM-PCGP) who were diagnosed
at 55 years and 2,713 Caucasian controls. These
SNPs were selected based on having the strongest
evidence in the published literature supporting an
association with PCa and, for rs1571801, with aggres-
sive PCa [14,16,17,19,25,26]. We found significant evi-
dence for an association (P < 0.05) between EO PCa
and 13 of the 14 SNPs, with the direction of the associ-
ation consistent with prior reports. Further, we show
that the EO PCa cases had a significantly greater aver-
age number of risk alleles across these SNPs than the
1,163 PCa cases from the Cancer Genetic Markers of
Susceptibility Study (CGEMS) study who were diag-
nosed with disease after age 55.
SUBJECTSANDMETHODS
StudySubjects
The study population consists of 754 unrelated
Caucasian American participants in the UM PCGP
diagnosed with histologically confirmed PCa (Inter-
national Classification of Diseases for Oncology code
C61.9) at 55 years of age. Dates of diagnosis were
obtained from the date of diagnostic biopsy for 96.6%
of cases, with the date of diagnosis for the remaining
cases determined from the date of trans-urethral
resection of the prostate, date of radical prostatectomy
or physician’s note. The majority of cases (95%) were
diagnosed between November, 1993 and February,
2006. Men were aged 27–55 years at diagnosis, with
average and median ages of 49.8 and 50 years,
respectively. Cases completed self-administered ques-
tionnaires that collected information on family history
of prostate and other cancers, medical history, and
demographic factors. In addition, detailed clinical
information relating to the diagnosis and treatment of
PCa, including Gleason score from biopsy, tumor
stage, and PSA level at diagnosis, was available from
medical records. Peripheral blood samples for prep-
aration of DNA were drawn from all subjects for gen-
otyping. All study procedures have been approved
by the University of Michigan Institutional Review
Board and were conducted in accordance with Health
Insurance Portability and Accountability Act (HIPAA)
regulations. Written informed consent was obtained
from all study participants prior to participation.
GenotypingEOPCaCases
Fourteen SNPs were selected for genotyping based
on published reports identifying them as significantly
associated with PCa: rs2660753 on 3p12, rs9364554
on 6q25, rs10486567 on 7p15, rs6465657 on 7q21,
rs6983267 and rs1447295 on 8q24, rs1571801 on 9q33,
rs10993994 on 10q11, rs4962416 on 10q26, rs7931342
on 11q13, rs4430796 on 17q12, rs1859962 on 17q24.3,
rs2735839 on 19q13, and rs5945619 on Xp11.22.
Applied Biosystems TaqManTM SNP assay system
was used to genotype individual DNA samples with
allelic discrimination performed on an ABI PRISM
7900HT Sequence Detection System. Any SNPs
remaining undetermined by the assay were directly
sequenced on an Applied Biosystems 3100 Genetic
Analyzer using Big Dye version 1.1 chemistries for a
final overall average 99.1% call completion, with no
individual SNP below 95.6% completion. Quality con-
trol included duplicate genotyping of 5% of the
148 Lange et al.
The Prostate
samples, distributed evenly among TaqManTM geno-
typing batches. Out of 897 duplicate paired genotype
calls, 16 genotype calls were discrepant, correspond-
ing to 98.2% agreement overall. In total 658 cases had
complete genotype data on all 14 SNPs.
iControlDBandCGEMSStudySubjects
An independent set of 2,713 unrelated controls
of Caucasian ancestry with available genotype data
were obtained from Illumina’s iControlDB database
(www.illumina.com/science/icontroldb.ilmn), that
is, iControls, as a comparison group for the UM EO
PCa cases. Subjects were anonymous but had infor-
mation available on age, sex, and ancestry. iControls
were genotyped with Illumina’s HumanHap550v1
(referred to as V1 subjects; n ¼ 1,197) or Human-
Hap550v3 (referred to as V3 subjects; n ¼ 1,516)
genome-wide genotyping platforms. The use of iCon-
trols in genetic association studies has been docu-
mented previously [27,28]. Genotype data for all 14
SNPs considered in this study were available in both
V1 and V3 iControl samples. For SNP rs5945619,
located on the X chromosome, the allele from each
male and a single randomly chosen allele from each
female in the iControls constituted the iControl
sample for this SNP.
Caucasian PCa cases (n ¼ 1,163) and screened con-
trols (n ¼ 1,113) in the CGEMS GWAS were included
as additional comparison groups to our EO PCa cases.
PCa cases and controls in the initial CGEMS GWAS
were participants in the control arm of the Prostate,
Lung, Colorectal and Ovarian (PLCO) Cancer Screen-
ing Trial [29]. All CGEMS cases and controls were
PSA screened; cases were 55–74 years at diagnosis,
with an average age at diagnosis >60 years. CGEMS
samples were genotyped using the Illumina Human-
Hap300 and HumanHap240 chips. Data were avail-
able for all 14 SNPs investigated in this report.
StatisticalAnalyses
The observed genotype distributions for each SNP
were tested for consistency with Hardy–Weinberg
equilibrium (HWE) expected proportions using
1-degree-of-freedom Pearson chi-square tests in the
EO PCa cases and iControls, respectively, using the
PLINK software [30] version 1.06 (available from
www.pngu.mgh.harvard.edu/purcell/plink). Uncon-
ditional logistic regression models were used to
evaluate the association between EO PCa and SNP
genotypes assuming a multiplicative, that is, log-
additive, genetic inheritance model. Statistical signi-
ficance was assessed using 1-degree-of-freedom
likelihood-ratio tests. Both two-sided and one-sided
hypothesis tests were performed, with the direction
of the one-sided test determined from prior published
studies (see Table II for relevant references). Statistical
analyses were performed using SAS version 9.1.3 soft-
ware package (SAS Institute, Cary, NC). Similar
analyses were performed using screened controls
from the CGEMS GWAS as the comparison group.
Finally, allelic-based likelihood ratio tests were used
to systematically test for differences in the ‘‘risk’’
allele frequencies between EO PCa cases and PCa
cases diagnosed after age 55 years, that is, CGEMS
PCa cases, for each SNP.
To assess whether the cumulative number of risk
alleles across the 13 PCa-associated SNPs was associ-
ated with EO PCa and whether EO PCa cases carry
more risk alleles on average than older-onset PCa
cases, we calculated the total number of risk alleles in
each case and each control sample (i.e., EO PCa and
CGEMS PCa cases and iControls and CGEMS con-
trols). SNP rs2660753 was not included in these calcu-
lations as it was not significantly associated with PCa
in the current study, the CGEMS study, nor in a large
study of 7,370 PCa cases and 5,742 controls by the
PRACTICAL consortium [15]. Individual subjects
missing genotype data for any of the 13 SNPs used in
calculating the sum of risk alleles were excluded from
this calculation. Unconditional logistic regression
models were used to test whether there were signifi-
cant differences in the total number of risk alleles
between EO PCa cases and iControls and between EO
PCa and CGEMS PCa cases. Unconditional logistic
regression was also used to evaluate the performance
of iControls as a reference group by comparing the
distribution of allele frequencies between iControls
and CGEMS controls.
Finally, case-only analyses were performed to
assess whether SNP genotypes were associated with
clinical features observed in our EO PCa cases,
specifically, age at diagnosis, biopsy, or pathological
Gleason score, and serum PSA at diagnosis. Single-
SNP case-only analyses were performed using logistic
regression (for dichotomous outcomes: family history
and aggressive disease) and Spearman’s rank corre-
lation (for continuous outcomes: age, Gleason score,
and pre-treatment serum PSA at diagnosis). Disease
aggressiveness has been defined previously [31] and
is similar to the definition used by the International
Consortium for Prostate Cancer Genetics [32].
Analyses were repeated using the cumulative number
of risk alleles as a continuous predictor of clinical fea-
tures of EO PCa.
RESULTS
The majority (63.8%) of EO PCa cases reported a
positive family history of PCa, with over 40% having
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a confirmed, first-degree affected relative (Table I).
Clinically, 76% of cases presented with serum PSA
level at diagnosis 4.0 ng/ml and 8.1% had clinical
Gleason scores 8–10. Overall, 29.8% of men with EO
disease were diagnosed with aggressive PCa, as
defined in Lange et al. [31] All SNPs in EO PCa cases
and 13 of 14 SNPs in iControls had genotype frequen-
cies consistent (P > 0.001) with HWE. Among iCon-
trols, SNP rs4430796 had an observed genotype
distribution inconsistent with HWE (P ¼ 4.4  104,
deficit of heterozygotes compared to expectation).
Upon further inspection, 112/1,197 V1 samples had a
missing genotype call (compared to 4/1,516 V3
samples) for this SNP. Sample-specific testing for
HWE revealed that the genotype distribution for
rs4430796 was consistent with HWE among V3
samples, but not among V1 samples (P ¼ 6.1  104).
Thirteen of the 14 studied SNPs, excluding
rs2660753, demonstrated evidence (P < 0.05) of
association with EO PCa. All 13 associated SNPs had
a direction of effect consistent with previous reports
(Table II). Ten of the 13 SNPs remained statistically
significant after strict application of the Bonferroni
correction for multiple testing to the one-sided test
results (i.e., P(one-sided) < 0.0036), while all 13 SNPs
remained statistically significant after applying
Holm’s less conservative sequential rejection method
(i.e., the Holm–Bonferroni method) for multiple test-
ing [33] (data not shown). Similar results were
obtained when CGEMS controls were utilized as the
reference group (Table III). SNP rs4430796 was signifi-
cantly associated with EO PCa when using either V1
(P ¼ 1.8  104, OR ¼ 1.28) or V3 (P ¼ 3.2  106,
OR ¼ 1.34) iControl samples. No significant evidence
for an association was observed between rs2660753
and EO PCa using the combined iControl samples or
when restricting the iControl samples to V1 (P ¼ 0.88,
OR ¼ 0.99) or V3 (P ¼ 0.06, OR ¼ 0.84) samples. In
addition, the odds ratio observed between EO PCa
and rs2660753 based on V3 control samples was in the
opposite direction to the previous report by Eeles
et al.[14] Finally, the total number of risk alleles
observed in each subject (measured as the sum of
risk alleles across 13 SNPs excluding rs2660753) was
strongly associated with EO PCa (P ¼ 2.1  1033,
Table IV and Fig. 1).
TABLE I. SampleCharacteristics for754Early-OnsetProstateCancerCases
Clinical features
EO cases
Rangen ¼ 754 %
Age at diagnosis (years)a 49.8 (3.9) 50.5 34–55
34–45 105 13.9
46–50 272 36.1
51–55 377 50.0
Number of affected family membersa,b 1.4 (1.8) 1 0–17
0 273 36.2
1 481 63.8
Family history of prostate cancer
1st degree relative (confirmed) 310 41.1
2nd degree relative (confirmed) 83 11.0
1st or 2nd degree relative (unconfirmed) 73 9.7
3rd degree relative (unconfirmed) 15 2.0
Serum PSA (ng/ml)a,c 22.9 (218.7) 5.4 0.3–5428
<4.0 172 24.0
4.0–9.9 403 56.1
10 143 19.9
Gleason Scorea 6.4 (0.9) 6.0 3–10
3–6 446 61.0
7 227 31.1
8–10 58 7.9
Aggressive diseased
No 529 70.2
Yes 225 29.8
aFor age at diagnosis, number of affected family members, and serum PSA statistics given are:
mean (SD), median, and range.
bTotal numbers of affected family members, not including the proband.
cSerum prostate-specific antigen (PSA) measured at diagnosis prior to treatment.
dAggressive disease defined as in Lange et al. [1].
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The frequencies of previously defined risk alleles
were higher among the younger EO PCa cases than
the older CGEMS cases. Specifically, the risk allele in
11 of the 13 SNPs was more common among EO PCa
cases (Table III). This difference was statistically sig-
nificant (P < 0.05) for five of the 11 SNPs. EO PCa
cases had significantly more total risk alleles across
the 13 SNPs than the PCa cases from the CGEMS
TABLE III. Distribution of SNPAllele Frequencies in Early Onset Prostate Cancer Cases Compared to CGEMs Cases and
Controls
SNP Chr. Alleles a
Early onset
cases allele freq.b
CGEMS controls (n ¼ 1,101) CGEMS cases (n ¼ 1,176)
Allele
freq.b OR (95% CI)c Pd
Allele
freq.b
%
Changee Pd
rs2660753 3p C/T 0.127 0.120 1.06 (0.87,1.30) 0.53 0.127 0.0 0.99
rs9364554 6q C/T 0.317 0.291 1.13 (0.98,1.30) 0.097 0.293 þ8.2 0.13
rs10486567 7p A/G 0.806 0.770 1.23 (1.05,1.47) 0.010 0.792 þ1.8 0.30
rs6465657 7q T/C 0.495 0.460 1.14 (1.00,1.30) 0.046 0.472 þ4.9 0.17
rs1447295 8q C/A 0.134 0.101 1.39 (1.13,1.70) 0.0020 0.144 6.9 0.36
rs6983267 8q T/G 0.606 0.489 1.60 (1.40,1.84) 3.7  1012 0.555 þ9.2 0.0021
rs1571801 9q G/T 0.274 0.242 1.18 (1.02,1.37) 0.029 0.285 3.9 0.47
rs4962416 10q A/G 0.326 0.264 1.34 (1.16,1.55) 6.4  1005 0.321 þ1.6 0.76
rs10993994 10q C/T 0.470 0.368 1.49 (1.31,1.70) 2.0  1009 0.413 þ13.8 5.6  1004
rs7931342 11q T/G 0.578 0.498 1.37 (1.20,1.56) 2.5  1006 0.543 þ6.4 0.033
rs1859962 17q T/G 0.534 0.486 1.21 (1.06,1.38) 0.0045 0.532 þ0.4 0.92
rs4430796 17q C/T 0.571 0.501 1.32 (1.15,1.51) 4.9  1005 0.541 þ5.5 0.082
rs2735839 19q A/G 0.888 0.844 1.45 (1.20,1.79) 1.4  1004 0.864 þ2.8 0.027
rs5945619 Xp T/C 0.432 0.336 1.50 (1.24,1.82) 3.2  1005 0.413 þ4.6 1.7  1004
aReference allele/allele associated with increased risk of prostate cancer as identified in prior studies, that is, the ‘‘risk’’ allele.
bFrequency of risk allele.
cOdds ratio and 95% confidence interval estimating the risk of prostate cancer associated with each additional copy of a risk allele,
assuming a log-additive genetic model.
dTwo-sided P-value.
ePercent change in risk allele frequency (þ/ increase or decrease, respectively) in EO compared to CGEMS Cases.
TABLE II. EarlyOnsetProstateCancerRiskAssociatedWithSNPsWhenComparedwithiControlDBPublicControls
SNP Chr. Allelesa
Frequency of risk allele
OR (95% CI)b P (two-sided) P (one-sided)c
Early-onset cases
(n ¼ 754)
iControls
(n ¼ 2,713)
rs2660753 [14] 3p C/T 0.127 0.140 0.90 (0.76, 1.07) 0.22 0.89
rs9364554 [14] 6q C/T 0.317 0.259 1.32 (1.17, 1.50) 1.3  1005 6.3  1006
rs10486567 [16] 7p A/G 0.806 0.761 1.30 (1.12, 1.49) 4.0  1004 2.0  1004
rs6465657 [14] 7q T/C 0.495 0.451 1.19 (1.06, 1.34) 0.0029 0.0015
rs1447295 [26] 8q C/A 0.134 0.099 1.41 (1.18, 1.67) 1.7  104 8.7  105
rs6983267 [19] 8q T/G 0.606 0.499 1.55 (1.38, 1.75) 1.9  1013 9.6  1014
rs1571801 [25] 9q G/T 0.274 0.245 1.16 (1.02, 1.32) 0.024 0.012
rs4962416 [16] 10q A/G 0.326 0.295 1.15 (1.02, 1.30) 0.023 0.012
rs10993994 [16] 10q C/T 0.470 0.422 1.21 (1.08, 1.36) 0.0011 5.5  1004
rs7931342 [14] 11q T/G 0.578 0.544 1.15 (1.03, 1.30) 0.017 0.0083
rs1859962 [17] 17q T/G 0.534 0.474 1.26 (1.12, 1.41) 6.4  1005 3.2  1005
rs4430796 [17] 17q C/T 0.571 0.499 1.31 (1.17, 1.47) 3.2  1006 1.6  1006
rs2735839 [14] 19q A/G 0.888 0.849 1.39 (1.18, 1.67) 1.9  1004 9.3  1005
rs5945619 [14] Xp T/C 0.432 0.364 1.33 (1.13, 1.57) 7.9  1004 3.9  1004
aReference allele/allele associated with increased risk of prostate cancer in prior studies.
bOdds ratio for each additional copy of risk allele (as identified in previous studies) assuming a multiplicative model.
cOne-sided test for direction of alternative hypothesis determined by prior study.
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study, with 12.42 risk alleles on average compared to
11.92 in CGEMS cases (P ¼ 1.7  105, Table IV). In
EO PCa case-only analyses, the frequency of the risk
allele at three SNPs, rs1048656 (P ¼ 0.012), rs1099399
(P ¼ 0.0087), and rs1859962 (P ¼ 0.037), was signifi-
cantly greater in men diagnosed with PCa prior to
age 50 (n ¼ 295) than in men diagnosed with PCa
between the ages of 50 and 55 years (n ¼ 459). Across
all 13 associated SNPs, there was significant evidence
for more total risk alleles in EO PCa cases diagnosed
prior to age 50 (12.81 risk alleles on average) than
in men diagnosed with PCa between the ages of 50
and 55 (12.13 risk alleles on average; P ¼ 0.0003,
Table IV).
There was no significant evidence for any associ-
ation between individual SNPs or total number of risk
alleles measured across the 13 associated SNPs and
pre-diagnostic serum PSA. The number of risk alleles
at rs2735839 was significantly negatively correlated,
after Bonferroni correction, with biopsy Gleason
score (Spearman’s correlation ¼ 0.12, P ¼ 0.0016).
One SNP was nominally significantly correlated
(P < 0.05) with Gleason score (rs1859962, Spearman’s
correlation ¼ 0.080, P ¼ 0.033). We found signifi-
cant evidence for a negative correlation between the
cumulative number of risk alleles across the 13 SNPs
associated with EO PCa and biopsy Gleason score
(Spearman’s correlation ¼ 0.085, P ¼ 0.032).
DISCUSSION
We performed a replication-based genetic associ-
ation study for 14 SNPs previously reported to be
associated with PCa in a sample of 754 Caucasian
American EO PCa cases from the UM-PCGP and
2,713 Caucasian American public controls from Illu-
mina’s iControlDB database. We found significant
evidence (P < 0.05) for an association between EO
TABLE IV. Cumulative Number of Risk Alleles for 13 SNPs in EOCases, iControlDB Controls,CGEMS Cases, and CGEMS
Controls
EO casesa,b
(n ¼ 754)
EO cases
50–55 yearsc
(n ¼ 459)
EO cases < 50 yrsc
(n ¼ 295)
iControlsa,d
(n ¼ 2,713)
CGEMS casesb
(n ¼ 1,1760
CGEMS controlsd
(n ¼ 1,101)
Mean 12.39 12.13 12.81 11.16 11.92 10.97
SD/SE 2.36/0.092 2.42/0.12 2.22/0.14 2.34/0.047 2.30/0.070 2.39/0.075
aEO cases compared to iControls (P ¼ 1.6  1032).
bEO cases compared to CGEMS cases (P ¼ 4.4  1005).
cEO cases diagnosed at <50 years versus EO cases diagnosed between 50 and 55 years (P ¼ 0.00030).
diControls versus CGEMS controls (P ¼ 0.033).
Fig. 1. Thedistributionof totalnumberofrisk alleles across13 SNPsinearlyonsetprostate cancercases compared to iControlDBcontrols,
CGEMScases, andCGEMScontrols.
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PCa and 13 of the 14 SNPs, but not rs2660753, with
similar direction of effect as in previous reports
[14,16,17,19,25,26]. For 11 of the 13 SNPs, the associ-
ation observed in the younger EO PCa cases was
stronger than those in the existing literature, which
reflect older case populations.
To our knowledge our study is the first to report
replication for an association between rs1571801 and
PCa, although we did not find any significant evi-
dence to support an increased frequency of the risk
allele in PCa cases with aggressive disease [data not
shown]. The association of rs1571801 with PCa was
first identified in a GWAS for aggressive PCa using
combined participants from the Cancer of the Prostate
in Sweden (CAPS) and CGEMS studies [25]. Interest-
ingly, as reported in Duggan et al. [25], the frequency
of the risk allele for rs1571801 was greater in non-
aggressive than in aggressive cases among CGEMS
samples. SNP rs1571801 was one of only two SNPs
(the other being rs1447295) with a higher risk allele
frequency in CGEMS compared to EO PCa cases.
Given that the association between rs1571801 and
PCa was previously identified in a study that
included CGEMS cases, the higher frequency of the
risk allele in CGEMS cases compared to our EO PCa
cases may be explained by the winner’s curse phenom-
enon [34].
SNPs rs4430796 and rs1859962 were first identified
by deCODE Genetics from a targeted follow-up study
to their original GWAS [26] that was initiated in
response to reports of linkage evidence to chromo-
some 17 in UM-PCGP and John’s Hopkins University
PCa pedigrees [17,31]. A subset of the UM-PCGP sub-
jects who were included in the reported linkage
analysis on chromosome 17 was also included in this
current association study. The association of PCa risk
with two SNPs at 8q24, rs1447295 and rs6983267, was
first reported by deCODE Genetics [26] and the
CGEMS GWAS study that expanded on the initial
findings at 8q24 [19], respectively. Two SNPs,
rs10486567 and rs4962416, were first reported in a fol-
low-up study to the initial GWAS by the CGEMS
study [16]. We note that our current study includes
only those CGEMS PCa cases included in the initial
GWAS [19]. The remaining seven SNPs (rs2660753,
rs9364554, rs6465657, rs10993994, rs7931342, rs2735839,
and rs5945619) were first reported in the early-onset
and familial PCa GWAS by Eeles et al. [14] and sub-
sequently followed-up in a confirmatory study in
7,370 PCa cases and 5,742 controls by the PRACTI-
CAL consortium [15]. In this follow-up study, strong
supporting evidence for six of the seven SNPs
(excluding rs2660753) was reported.
We used a public control population of Caucasian
Americans that have been genotyped in several
studies using different genotyping platforms than the
platform used to genotype our study cases. The iCon-
trols were genotyped on Illumina’s HumanHap550v1
and HumanHap550v3 Beadchip genome-wide SNP
platforms compared to the UM-PCGP cases, who
were genotyped using Applied Biosystems TaqMan
assays. It is possible that the use of different genotyp-
ing platforms in cases and controls could have led to
a systematic bias or batch effect in genotyping calls.
Public controls were selected for use in this study
based on the limited availability of unrelated controls
for genotyping to UM-PCGP investigators and the
availability of a large number of reference samples’
control genotypes though Illumina’s iControlDB data-
base. We note that the iControlDB samples have been
genotyped using the same Illumina Beadchip technol-
ogy used in several recent PCa genome-wide studies.
While we cannot definitively rule out the possibility
of bias resulting from a batch genotyping effect, we
note that the direction of the association between EO
PCa and 13 SNPs was consistent with previous
reports. Further, the allele frequencies for the SNPs
were similar between the two independent V1 and V3
iControlDB samples. Prior GWA studies that have
included the iControlDB samples have not noted the
presence of any major genotype call bias in their
reports [27,28]. Most importantly, we note that our
results did not differ when we used the CGEMS con-
trols’ genotype distribution as the reference group
(Table III) and that our case-only results are not sub-
ject to any such possible bias.
EO PCa has been shown to be significantly associ-
ated with increased family history of the disease, pro-
viding evidence of a stronger underlying genetic
etiology of EO disease than for late-onset disease. To
date, several multistage GWA studies for PCa have
been conducted using a variety of rules for PCa case
inclusion. The GWAS based on younger (i.e., 60
years) PCa cases and cases with a positive family
history of PCa by Eeles et al. [14] demonstrated the
increased power for detecting SNPs associated with
PCa that can be achieved by including cases with
enriched genetic susceptibility to the disease. Eeles
et al.[14] found significant evidence of association for
seven novel SNPs (P < 1.0  107) in their stage 1
results in addition to the widely reported PCa
susceptibility loci on chromosomes 8q24 and 17q.
Although an association with age of diagnosis has
been tested and rejected in many prior studies,
including the original GWAS reports that identified
the SNPs we have tested, the men included in all of
these studies were much older than those included
in the present study. On average, our EO PCa cases
were diagnosed at 49.8 years, 7 years younger than
the PCa cases in the study by Eeles et al. Furthermore,
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>60% of our cases had a family history of PCa in 1st
or 2nd degree relatives (52.1% confirmed, 9.7% un-
confirmed). We found significant evidence (P < 0.05)
supporting the association between EO PCa and 13 of
14 SNPs studied, with the same direction of effects as
in previous reports. We showed that the frequency of
risk alleles, for both individual SNPs and in aggregate
across SNPs, is significantly greater in EO PCa cases
than in CGEMs cases who were diagnosed at >55
years. Interestingly, we also found significant evi-
dence that the trend of more risk alleles in younger
cases compared to older cases existed among just our
EO PCa cases suggesting that the cumulative impact
of common genetic risk factors are particularly
important in men diagnosed with PCa prior to their
50th birthday.
In summary, our results provide strong evidence
that SNPs associated with overall PCa are also likely
to be associated with EO PCa and that studies focused
on EO PCa could be a particularly powerful resource
for future association studies focusing on PCa. From a
clinical perspective, these findings suggest that com-
mon genetic variants play an increased role in EO
PCa, relative to later onset PCa, and that greater
emphasis should be placed on measuring the cumu-
lative impact of these variants on EO PCa. It is likely
that novel common and rare high-penetrant genetic
variants exist and have yet to be identified that will
be particularly important in EO and familial PCa. We
are in the process of performing a GWAS and high-
throughput sequencing efforts that will focus on this
important set of patients with EO PCa.
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